Previous 10 | Next 10 |
2024-03-17 19:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-07 06:01:00 ET On March 4, analyst Joseph Pantginis at HC Wainwright opined that shares of Iovance Biotherapeutics (NASDAQ: IOVA) would reach $32, an increase of 91% beyond its current price near $17. There are a handful of reasons to believe that Pantginis' estimate wil...
2024-03-06 04:42:00 ET Iovance Biotherapeutics (NASDAQ: IOVA) stock fell on Feb. 29, the day after it reported its fourth-quarter earnings, but that didn't stop Goldman Sachs analyst Andrea Tan from issuing a sunny outlook, raising her price target for the stock from $19 to $21....
SAN CARLOS, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that t...
2024-03-02 06:50:00 ET Iovance Biotherapeutics (NASDAQ: IOVA) has been one of the hottest healthcare stocks in 2024. It has already doubled in value and investors are hopeful that there could still be more upside left for the shares now that regulators have approved one of its treat...
2024-02-29 17:47:00 ET Iovance Biotherapeutics (NASDAQ: IOVA) , one of the more high-flying biotech stocks of late, fell earthward in trading on Thursday. This was a direct consequence of its latest quarterly figures and operational update that were published after hours on Wednesda...
2024-02-29 05:51:00 ET Some investors are attracted to small biotech stocks because of their potential for explosive returns. It's not uncommon for these stocks to go parabolic after positive news is announced. That's exactly what happened to Iovance Biotherapeutics (NASDAQ: IOVA)...
Amtagvi™ (lifileucel) U.S. Launch Fully Underway Following U.S. Food and Drug Administration (FDA) Approval as the First and Only One-Time, Individualized T cell Therapy for a Solid Tumor Cancer Amtagvi Regulatory Submissions on Track in the European Union, United Kingdom, and Cana...
SilverBow Resorces Inc. (SBOW) is expected to report $2.36 for Q4 2023 FAT Brands Inc. Class B Common Stock (FATBB) is expected to report for quarter end 2023-12-31 Ecovyst Inc. (ECVT) is expected to report $0.2 for Q4 2023 MYR Group Inc. (MYRG) is expected to report $1.41 for Q4 2023...
2024-02-26 05:39:00 ET Investors looking for stocks that can produce swift and dramatic gains recently found what they wanted with Iovance Biotherapeutics (NASDAQ: IOVA) . Over the past three months, shares of the cancer drug developer nearly tripled in value. Despite an already...
News, Short Squeeze, Breakout and More Instantly...
Iovance Biotherapeutics Inc. Company Name:
IOVA Stock Symbol:
NASDAQ Market:
Iovance Biotherapeutics Inc. Website:
SAN CARLOS, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its first quarter 2024 ...
2024-04-28 14:44:00 ET There's a lot of excitement around Iovance Biotherapeutics (NASDAQ: IOVA) as its shares are up over 40% year-to-date. Investors and analysts both see even more upside for this mid-cap biotech stock in the long run. Today, however, the company remains deepl...
SAN CARLOS, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) ("Iovance" or the "Company"), a biote...